| Literature DB >> 27616271 |
Roberta Baravalle1, Francesca Valetti1, Gianluca Catucci1, Giovanna Gambarotta2, Mario Chiesa3, Sara Maurelli3, Elio Giamello3, Ines Barone4, Stefania Catalano4, Sebastiano Andò4, Giovanna Di Nardo5, Gianfranco Gilardi6.
Abstract
Aromatase catalyses the conversion of androgens into estrogens and is a well-known target for breast cancer therapy. As it has been suggested that its activity is affected by inhibitors of phosphodiesterase-5, this work investigates the potential interaction of sildenafil with aromatase. This is carried out both at molecular level through structural and kinetics assays applied to the purified enzyme, and at cellular level using neuronal and breast cancer cell lines. Sildenafil is found to bind to aromatase with a KD of 0.58±0.05μM acting as a partial and mixed inhibitor with a maximal inhibition of 35±2%. Hyperfine sublevel correlation spectroscopy and docking studies show that sildenafil binds to the heme iron via its 6th axial water ligand. These results also provide information on the starting molecular scaffold for the development of new generations of drugs designed to inhibit aromatase as well as phosphodiesterase-5, a new emerging target for breast cancer therapy. Copyright ÂEntities:
Keywords: Aromatase inhibitors; Breast cancer; Cytochromes P450; Estrogens; Sildenafil
Mesh:
Substances:
Year: 2016 PMID: 27616271 DOI: 10.1016/j.jsbmb.2016.09.003
Source DB: PubMed Journal: J Steroid Biochem Mol Biol ISSN: 0960-0760 Impact factor: 4.292